Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

TCGA-BH-A0E6-01A-11R-A034-07

— · E

972a1b9e-98b9-5a18-9ea2-a61c54f972ac

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
E
subtype
E
overall_survival_months
10

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.520
  • MYC_TARGETS_V1+0.320
  • PANCREAS_BETA_CELLS+0.300
  • KRAS_SIGNALING_DN+0.290
  • MYOGENESIS+0.270
  • ALLOGRAFT_REJECTION+0.260
  • COAGULATION+0.240
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.230
  • OXIDATIVE_PHOSPHORYLATION+0.190
  • E2F_TARGETS+0.180

Top 10 suppressed

  • PROTEIN_SECRETION-0.510
  • ANDROGEN_RESPONSE-0.380
  • UV_RESPONSE_DN-0.350
  • INTERFERON_ALPHA_RESPONSE-0.340
  • TGF_BETA_SIGNALING-0.320
  • MITOTIC_SPINDLE-0.290
  • TNFA_SIGNALING_VIA_NFKB-0.250
  • APOPTOSIS-0.240
  • ESTROGEN_RESPONSE_EARLY-0.240
  • INTERFERON_GAMMA_RESPONSE-0.240

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-B6-A409-01A-11R-A24H-07
breast-umap@18
—E0.785
2TCGA-A2-A3XX-01A-21R-A239-07
breast-umap@18
—E0.775
3TCGA-E2-A574-01A-11R-A29R-07
breast-umap@18
—E0.746
4SRR2016952
head-neck@1
——0.745
5MNG192
mng-umap@100
——0.734
6TCGA-A2-A3XS-01A-11R-A22U-07
breast-umap@18
—E0.713
7SRR9879286
lung-landscapes@6
—cohortSQ20.712
8MDT-AP-1338
medullo-epn-umap@date-based
MedMedulloblastoma0.698
9MNG154
mng-umap@100
——0.696
10SRR650168
bladder-landscape@3
——0.694

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.520Idelalisib— uncovered
MYC_TARGETS_V10.320Inavolisib— uncovered
PANCREAS_BETA_CELLS0.300Cobimetinib— uncovered
KRAS_SIGNALING_DN0.290Remibrutinib— uncovered
MYOGENESIS0.270Inavolisib— uncovered
ALLOGRAFT_REJECTION0.260Idelalisib— uncovered
COAGULATION0.240Binimetinib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.230Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.190Remibrutinib— uncovered
E2F_TARGETS0.180Inavolisib— uncovered
APICAL_JUNCTION0.160Inavolisib— uncovered
HEDGEHOG_SIGNALING0.160Inavolisib— uncovered
GLYCOLYSIS0.120Inavolisib— uncovered
UV_RESPONSE_UP0.120Idelalisib— uncovered
SPERMATOGENESIS0.110Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.090Inavolisib— uncovered
G2M_CHECKPOINT0.060Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.040Inavolisib— uncovered
KRAS_SIGNALING_UP0.040Inavolisib— uncovered
ADIPOGENESIS0.030Inavolisib— uncovered